Amneal Pharmaceuticals (AMRX) Competitors $8.24 -0.02 (-0.24%) Closing price 04:00 PM EasternExtended Trading$8.24 +0.00 (+0.06%) As of 04:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock AMRX vs. BBIO, VRNA, BPMC, ROIV, ELAN, RGC, LEGN, RVMD, GRFS, and TGTXShould you be buying Amneal Pharmaceuticals stock or one of its competitors? The main competitors of Amneal Pharmaceuticals include BridgeBio Pharma (BBIO), Verona Pharma PLC American Depositary Share (VRNA), Blueprint Medicines (BPMC), Roivant Sciences (ROIV), Elanco Animal Health (ELAN), Regencell Bioscience (RGC), Legend Biotech (LEGN), Revolution Medicines (RVMD), Grifols (GRFS), and TG Therapeutics (TGTX). These companies are all part of the "pharmaceutical products" industry. Amneal Pharmaceuticals vs. Its Competitors BridgeBio Pharma Verona Pharma PLC American Depositary Share Blueprint Medicines Roivant Sciences Elanco Animal Health Regencell Bioscience Legend Biotech Revolution Medicines Grifols TG Therapeutics BridgeBio Pharma (NASDAQ:BBIO) and Amneal Pharmaceuticals (NASDAQ:AMRX) are both mid-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, institutional ownership, dividends, valuation, media sentiment, analyst recommendations, earnings and risk. Do analysts rate BBIO or AMRX? BridgeBio Pharma currently has a consensus target price of $61.20, indicating a potential upside of 30.94%. Amneal Pharmaceuticals has a consensus target price of $11.60, indicating a potential upside of 40.78%. Given Amneal Pharmaceuticals' higher possible upside, analysts clearly believe Amneal Pharmaceuticals is more favorable than BridgeBio Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BridgeBio Pharma 0 Sell rating(s) 0 Hold rating(s) 15 Buy rating(s) 0 Strong Buy rating(s) 3.00Amneal Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media favor BBIO or AMRX? In the previous week, BridgeBio Pharma had 23 more articles in the media than Amneal Pharmaceuticals. MarketBeat recorded 25 mentions for BridgeBio Pharma and 2 mentions for Amneal Pharmaceuticals. Amneal Pharmaceuticals' average media sentiment score of 0.95 beat BridgeBio Pharma's score of 0.64 indicating that Amneal Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BridgeBio Pharma 8 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Amneal Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders & institutionals believe in BBIO or AMRX? 99.9% of BridgeBio Pharma shares are owned by institutional investors. Comparatively, 31.8% of Amneal Pharmaceuticals shares are owned by institutional investors. 18.2% of BridgeBio Pharma shares are owned by company insiders. Comparatively, 26.6% of Amneal Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Is BBIO or AMRX more profitable? Amneal Pharmaceuticals has a net margin of -0.46% compared to BridgeBio Pharma's net margin of -524.25%. BridgeBio Pharma's return on equity of 0.00% beat Amneal Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets BridgeBio Pharma-524.25% N/A -94.43% Amneal Pharmaceuticals -0.46%-188.26%5.34% Which has stronger earnings and valuation, BBIO or AMRX? Amneal Pharmaceuticals has higher revenue and earnings than BridgeBio Pharma. Amneal Pharmaceuticals is trading at a lower price-to-earnings ratio than BridgeBio Pharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBridgeBio Pharma$221.90M40.00-$535.76M-$3.53-13.24Amneal Pharmaceuticals$2.79B0.92-$116.89M-$0.04-206.00 Which has more risk & volatility, BBIO or AMRX? BridgeBio Pharma has a beta of 1.15, meaning that its stock price is 15% more volatile than the S&P 500. Comparatively, Amneal Pharmaceuticals has a beta of 1.06, meaning that its stock price is 6% more volatile than the S&P 500. SummaryAmneal Pharmaceuticals beats BridgeBio Pharma on 8 of the 15 factors compared between the two stocks. Get Amneal Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for AMRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AMRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AMRX vs. The Competition Export to ExcelMetricAmneal PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.58B$2.44B$5.50B$9.39BDividend YieldN/A1.79%4.25%4.09%P/E Ratio-205.959.1828.1019.86Price / Sales0.92470.43402.2879.25Price / Cash5.95160.6835.5357.53Price / Book-23.544.748.265.72Net Income-$116.89M$30.99M$3.24B$257.80M7 Day Performance-1.79%1.00%0.50%1.06%1 Month Performance4.30%10.07%7.99%11.30%1 Year Performance10.90%-3.63%28.68%17.00% Amneal Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AMRXAmneal Pharmaceuticals2.8574 of 5 stars$8.24-0.2%$11.60+40.8%+8.7%$2.58B$2.79B-205.958,100BBIOBridgeBio Pharma4.6415 of 5 stars$47.69+2.6%$61.20+28.3%+61.0%$9.06B$221.90M-13.51400Analyst ForecastAnalyst RevisionVRNAVerona Pharma PLC American Depositary Share2.3057 of 5 stars$104.67-0.2%$109.00+4.1%+370.5%$8.91B$42.28M-52.3430Analyst ForecastHigh Trading VolumeBPMCBlueprint Medicines1.1282 of 5 stars$129.36+0.0%$128.25-0.9%+7.3%$8.35B$508.82M-52.37640Positive NewsHigh Trading VolumeROIVRoivant Sciences2.6493 of 5 stars$11.63+2.4%$16.50+41.9%-0.6%$7.91B$29.05M-46.52860Positive NewsELANElanco Animal Health1.5736 of 5 stars$14.88-0.2%$15.33+3.1%+9.5%$7.39B$4.44B20.109,000Analyst UpgradeGap UpRGCRegencell Bioscience0.3346 of 5 stars$14.68-0.5%N/AN/A$7.29BN/A0.0010Positive NewsGap UpLEGNLegend Biotech3.6478 of 5 stars$39.44+1.2%$72.70+84.3%-28.9%$7.25B$627.24M-66.852,609News CoveragePositive NewsAnalyst ForecastGap UpRVMDRevolution Medicines4.5405 of 5 stars$38.37+0.9%$68.00+77.2%-17.9%$7.15B$11.58M-9.59250Analyst ForecastGRFSGrifols3.5421 of 5 stars$9.72-0.2%$10.30+6.0%+23.8%$6.68B$7.81B8.3123,822Gap UpTGTXTG Therapeutics3.395 of 5 stars$38.92+5.0%$43.80+12.5%+72.5%$6.18B$329M162.17290 Related Companies and Tools Related Companies BBIO Competitors VRNA Competitors BPMC Competitors ROIV Competitors ELAN Competitors RGC Competitors LEGN Competitors RVMD Competitors GRFS Competitors TGTX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AMRX) was last updated on 7/17/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amneal Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Amneal Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
